NCT06996093View on ClinicalTrials.gov

Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

2,508

Participants

Timeline

Start Date

June 2, 2025

Primary Completion Date

June 1, 2030

Study Completion Date

June 1, 2034

Conditions
Breast Cancer
Interventions
DRUG

4 cycles of TC (docetaxel + cyclophosphamide) adjuvant chemotherapy

4 cycles of TC (docetaxel + cyclophosphamide) adjuvant chemotherapy

DRUG

aromatase inhibitor (± ovarian suppression) plus CDK4/6 inhibitor

aromatase inhibitor (± ovarian suppression) plus CDK4/6 inhibitor

Trial Locations (1)

200032

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER